Ixazomib (MLN2238)
MLN2238 inhibits the chymotrypsin-like proteolytic (?5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (?1) and trypsin-like (?2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.
